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EDITORIAL
Sprue-Like  Enteropathy  Associated  With Olmesartan:
A New  Kid  on the  Enteropathy  Block
Enteropatia  Tipo  Sprue  Induzida  Por  Olmesartan:  Uma  Nova  Entidade  no
Campo  Das  Enteropatias
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Sprue-like  enteropathy  associated  with  olmesartan,  ﬁrst
identiﬁed  by  our  group  in  2012,1 is  characterized  by  chronic
diarrhea  (often  severe)  and  weight  loss  that  is  unresponsive
to  a  gluten-free  diet.  Laboratory  work-up  commonly  reveals
non-speciﬁc  anemia,  hypoalbuminemia,  electrolyte  imbal-
ance,  and  vitamin  deﬁciencies,  consistent  with  a  severe
malabsorption  process.  Histopathological  ﬁndings  include  a
combination  of  duodenal  villous  atrophy,  increased  intraep-
ithelial  lymphocytes,  and  a  thickened  subepithelial  collagen
layer  (collagenous  sprue).  Histologic  changes  can  be  limited
to  the  small  bowel,  or  may  include  the  entire  gastroin-
testinal  tract,  with  ﬁndings  such  as  lymphocytic/collagenous
gastritis  and  colitis.  Individuals  with  sprue-like  enteropathy
associated  with  olmesartan  have  negative  celiac  serology.
The  majority  may  have  either  HLA-DQ2  or  DQ8  haplotypes
(61--81%).1 Diagnosis  of  olmesartan  associated  enteropathy
should  therefore  be  considered  in  cases  of  villous  atrophy
with  negative  celiac  serology  (so-called  seronegative  villous
atrophy).  Conﬁrmation  of  diagnosis  requires  clinical  reso-
lution  of  symptoms  after  olmesartan  withdrawal.  Mucosal
recovery  is  also  expected  within  3--6  months  of  olmesartan
withdrawal  and  a  follow-up  duodenal  biopsy  is  reasonable.
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Severe  sprue-like  enteropathy  associated  with  olmesar-
an  appears  to  be  rare  although  a  spectrum  of  disease
everity  may  be  possible.2 The  annual  incidence  rate  of
nteropathy  in  a  French  population-based  study  among
atients  treated  with  olmesartan  for  at  least  6  months
as  calculated  at  1.3  cases  per  1000  individuals  per  year
95%  conﬁdence  interval  (CI)  of  0.5--2.6).3 This  rate  is  not
igniﬁcantly  different  from  the  rate  of  0.63  cases  of  inci-
ent  celiac  disease  per  1000  reported  by  the  Mini-Sentinel
95%  CI:  .38--.99)  (p  =  0.16).4 The  Mini-Sentinel  reported  that
ates  of  incident  celiac  disease  were  of  similar  magnitude
or  all  angiotensin  receptor  blockers  with,  for  instance,  a
ate  of  0.43  cases  per  1000  (95%  CI:  0.33--0.55)  for  losar-
an.  Mini-Sentinel  data  therefore  suggest  that  enteropathy
ay  be  a  class-related  drug  effect.  Such  a  hypothesis  is
upported  by  sporadic  case-reports  of  enteropathy  possi-
ly  associated  with  irbesartan,5 losartan,6 and  valsartan.7
owever,  a  nation-wide  case-control  Swedish  study  failed  to
how  any  association  between  the  use  of  either  angiotensin
onverting  enzyme  blockers  or  non-olmesartan  angiotensin
eceptor  blockers  and  subsequent  villous  atrophy.8 Thus,
here  is  clear  predominance  of  published  data  relating  olme-
artan  to  enteropathy  (Table  1).
Sprue-like  enteropathy  associated  with  olmesartan
hould  be  ruled  out  early  in  the  investigation  of  patients
ith  seronegative  villous  atrophy.  Indeed,  a  case-series
n  72  patients  with  seronegative  villous  atrophy  found
he  most  frequent  etiologies  to  be  seronegative  CD
28%),  medication-related  (26%),  unclassiﬁed  sprue  (14%),
utoimmune  enteropathy  (4%),  and  giardia  (4%).13 Of  the
 by Elsevier España, S.L.U. This is an open access article under the
.0/).
62  I.A.  Hujoel,  A.  Rubio-Tapia
Table  1  Case-reports  and  case-series  of  sprue-like  enteropathy  associated  with  olmesartan  published  after  the  Mayo  Clinic
2012 original  case-series.
Reference
number
Author Country Date of
Publication
Number of
cases
Comments
9 Talbot USA 2012 1 Follow up histology: no
10 Dreifuss et al. USA 2013 1 Follow up histology: no
11 Nielsen et al. USA 2013 1 Follow up histology: yes
Time  after cessation: 3 months
Resolution  of histologic changes: yes
12 Stanich et al. USA 2013 1 Follow up histology: no
13 DeGaetani et al. USA 2013 16 Follow up histology: 2/16
Time  after cessation: 12 months
Resolution  of histologic changes: yes (2/2)
14 Abdelghany et al. USA 2014 1 Follow up histology: no
15 Tran et al. USA 2014 1 Follow up histology: no
16 Théophile et al. France 2014 5 Follow up histology: yes (2/5), no (3/5)
Time  after cessation: 2 months (2/2)
Resolution of histologic changes: yes (1/2),
partial  (1/2; IELs still present but VA resolved)
17 Gaur et al. USA 2014 1 Follow up histology: no
18 Fiorucci et al. Italy 2014 1 Follow up histology: no
19 Khan et al. USA 2014 1 Follow up histology: no
20 Hartranft et al. USA 2014 1 Follow up histology: no
21 Ianiro et al. Italy 2014 3 Follow up histology: 3/3
Time  after cessation: 3 months (2/3), not
reported  (1/3)
Resolution of histologic changes: yes 2/3, partial
(1/3)
22 Gallivan et al. Australia 2014 1 Follow up histology: yes
Time  after cessation: 4 months
Resolution  of histologic changes: yes
5 Marthey et al. France 2014 36 Follow up histology: 15/36
Time  after cessation: 9 months
Resolution  of histologic changes: yes (15/15)
23 Scialom et al. France 2015 7 Follow up histology: 5/7
Time  after cessation: 2-7 months
Resolution of histologic changes: yes (4/5); one
had  biopsy while on anti-TNF-antibodies and
olmesartan  discontinued with resolution of
histologic  changes (1/5)
24 Kulai et al. Canada 2015 1 Follow up histology: yes
Time  after cessation: 14 weeks
Resolution  of histologic changes: yes
25 Mun˜oz- Mun˜oz et al. Spain 2015 1 Follow up histology: no
26 Marco-Marqués et al. Spain 2015 11 Follow up histology: no
27 Heerasing et al. Australia 2015 1 Follow up histology: yes
Time  after cessation: 4 months
Resolution  of histologic changes: yes
28 Fabian et al. Austria 2015 1 Follow up histology: yes
Time  after cessation: 2 months
Resolution  of histologic changes: yes
29 Fukushima et al. Japan 2016 1 Follow up histology: yes
Time  after cessation: 11 months
Resolution  of histologic changes: yes
30 Imperatore et al. Italy 2016 1 Follow up histology: yes
Time  after cessation: 8 months
Resolution  of histologic changes: yes
31 Schiepatti et al. Italy 2016 2 Follow up histology: Yes (2/2)
Time  after cessation: 2 months (2/2)
Resolution of histologic changes: yes (2/2)
3 Esteve et al. Spain 2016 20 Follow up histology: yes (19/20)
Time  after cessation: 3--12 months
Resolution of histologic changes: yes (18/19), no
(1/19)
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medication-related  seronegative  villous  atrophy,  roughly
84%  were  attributed  to  olmesartan.13 Early  identiﬁcation
of  individuals  with  sprue-like  enteropathy  associated  with
olmesartan  is  clinically  relevant  as  symptoms  can  be  severe
and/or  life-threatening  with  expected  clinical  response
within  days  of  olmesartan  withdrawal.1
In  this  issue  of  GE  Portuguese  Journal  of  Gastroenter-
32 33ology, case  reports  by  da  Silva  et  al. ,  Carneiro  et  al.
and  Eusébio  et  al.34,  highlight  the  importance  of  consider-
ing  sprue-like  enteropathy  associated  with  olmesartan  when
approaching  a  patient  with  seronegative  villous  atrophy  and
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Figure  1  Proposed  Management  for  Patients  with  Sprue-like  Ente
includes (but  it  is  not  limited  to)  seronegative  celiac  disease,  other  
sprue, small-bowel  bacterial  overgrowth,  hypogammaglobulinemic  s
collagenous sprue,  and  unclassiﬁed  sprue.  2.  If  there  is  a  need  for
different class  of  medication  whenever  is  clinically  possible.63
rovide  further  information  to  aid  in  diagnosis  of  this  emer-
ent  disease.
In  their  case-report,  da  Silva  et  al.  outline  a  practi-
al  algorithm  to  approach  diagnosis  of  seronegative  villous
trophy  that  does  not  respond  to  a  gluten  free  diet.32 The
rst  proposed  step  following  testing  for  celiac  serology  is
 review  of  the  patient’s  medication  list.  In  the  four  cases
eported  in  this  issue,  symptoms  resolved  within  48  h  to  one
eek  of  discontinuation  of  olmesartan.32--34 Trialing  a  patient
ff  of  a  medication  early  on  in  the  evaluation  of  seroneg-
tive  villous  atrophy  could  therefore  provide  both  a  rapid
ropathy  associated  with  Olmesartan.  1.  Differential  diagnosis
drug-related  enteropathies,  autoimmune  enteropathy,  tropical
prue,  Giardiasis,  refractory  celiac  disease,  Whipple’s  disease,
 continuation  of  alternative  therapy,  we  recommend  to  use  a
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24  
nd  cost-effective  diagnosis.  It  is  our  practice  that  following
lmesartan  withdrawal,  we  try  to  understand  the  primary
ndication  for  olmesartan  therapy  and  reassess  the  need  for
lternative  medications  together  with  the  patient’s  primary
are  physician.  It  has  been  our  experience  that  a  consider-
ble  number  of  patients  do  not  need  any  medications  after
uspension  of  olmesartan.
Eusébio  et  al.34 identify  a  unique  ﬁnding  of  elevated
ransaminases  in  a  case  of  olmesartan  associated  enteropa-
hy.  They  propose  that  this  may  be  due  to  the  same
echanism  behind  the  hypertransaminasemia  seen  in  CD.
Carneiro  et  al.33 report  on  a  case  diagnosed  with  systemic
clerosis  during  the  work-up  for  sprue-like  enteropathy  asso-
iated  with  olmesartan.  The  association  with  autoimmune
iseases  has  been  reported  in  several  other  studies.3,5,23
n  line  with  this  observation,  there  are  reports  of  individ-
als  with  sprue-like  enteropathy  associated  with  olmesartan
esponding  to  immunosuppressive  treatment.5,23 Our  open-
abel  experience  suggests  that  some  patients  with  severe
ymptoms,  recurrent  hospitalizations  due  to  dehydration  or
oth  slow  and/or  partial  response  to  olmesartan  withdrawal
ay  have  some  beneﬁt  from  a  short  course  of  steroids  such
s  budesonide  (Fig.  1).
The  association  between  autoimmune  diseases  and
lmesartan  associated  enteropathy  is  consistent  with  the
merging  evidence  supporting  an  immune-based  pathophy-
iology.  One  recent  study  by  our  group  looking  at  duodenal
iopsies  of  those  taking  olmesartan  versus  those  who  had
iscontinued  the  medication  showed  an  increased  CD8+
ells,  FoxP3+  cells,  and  IL15R  in  biopsies  of  those  taking
lmesartan,  similar  to  what  is  seen  in  CD.35 In  addition,
e  demonstrated  an  increased  IL15  expression  and  disrup-
ion  of  tight  junction  proteins  (ZO-1)  in  olmesartan-treated
aco-2  cells.35 This  suggests  that  olmesartan  may  trigger  a
imilar  change  in  intestinal  epithelial  cells  as  gluten  does
n  those  with  CD  although  further  study  of  the  underly-
ng  mechanisms  would  be  needed  to  fully  understand  the
athophysiology  of  sprue-like  enteropathy  associated  with
lmesartan,  the  new  kid  on  the  enteropathy  block.
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